LIDDS

SE0001958612

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 28/06/2024 pm IST			5-day change	1st Jan Change
0.13 ^SEK	+0.78%		+1.56%	+20.37%

30/05	LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
26/05	LIDDS AB Moves the Publication of the Interim Report for the First Quarter 2024	CI

LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2024

May 30, 2024 at 12:30 pm IST

LIDDS AB (publ) reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was SEK 0.023 million. Revenue was SEK 0.926 million.

Net loss was SEK 0.005 million.

Latest news about LIDDS AB

LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2024	30/05	CI
LIDDS AB Moves the Publication of the Interim Report for the First Quarter 2024	27/05	CI
LIDDS AB Announces CFO Changes, Effective 1 September 2024	14/05	CI
LIDDS AB Announces CEO Changes, Effective 1 September 2024	14/05	CI
Sweden's Lidds Finalizes Purchase of Noviga Research	21/03	MT
LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB.	21/03	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02	CI
LIDDS AB (OM:LIDDS) signed an agreement to acquire Noviga Research AB.	29/01	CI
LIDDS AB Approves Board Elections	09/01	CI
Lidds AB Announces Resignation of Daniel Lifveredson from Board of Directors	07/12	CI
Lidds CFO to Take Over CEO Role; Shares Plunge	28/11	MT
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11	CI
LIDDS AB Announces CEO Changes	28/11	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/23/30	CI
LIDDS AB Announces CEO Changes	31/23/31	CI
LIDDS AB Announces Closure of R&D Project with Johnson & Johnson Enterprise Innovation Inc	07/23/07	CI
Max Mitteregger Resigns from the LIDDS's Board	03/23/03	CI
Anders MÃ¥nsson Plans to Leave the LIDDS AB as CEO	27/23/27	CI
LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2023	29/23/29	CI
LIDDS AB Announces Management Changes	13/23/13	CI
LIDDS AB Reports Earnings Results for the Full Year Ended December 31, 2022	13/23/13	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	13/23/13	CI
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	28/22/28	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/22/25	CI
LIDDS AB Announces CEO Changes	15/22/15	CI

Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Companyâs portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LIDDS AB	+20.37%	1.66M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	122B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.49B
BIONTECH SE	-23.86%	19.4B
GENMAB A/S	-19.03%	16.24B
BEIGENE, LTD.	-20.90%	15.4B
WUXI APPTEC CO., LTD.	-46.14%	15.15B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.52B

Bio Therapeutic Drugs

LIDDS AB

Equities

LIDDS

SE0001958612

Biotechnology & Medical Research

LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2024

Latest news about LIDDS AB

Chart LIDDS AB

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs